Loading data for PLUR — first visit, this takes a few seconds.
Pluri Inc. (PLUR)
NasdaqCM: PLUR
· Real-Time Price · USD
1.66
+0.10 (6.41%)
At close: Aug 26, 2026, 8:00 PM
1.51
+2.03%
Pre-market: 4:22 AM
The price, the headline numbers and the latest news, in one place.
Pluri Inc. (PLUR) Stock Price, Analysis & Data
6.41% (1D)
No data available
| Bid | 1.57 |
| Market Cap | 15.97M |
| Revenue (ttm) | 1.08M |
| Net Income (ttm) | -25.54M |
| 0.68 | |
| -2.9 | |
| n/a | |
| -0.78 | |
| P/B (ttm) | -0.83 |
| P/S (ttm) | 14.80 |
| Earnings Date | n/a |
| Ask | 1.61 |
| Volume | 18,814 |
| Avg. Volume (20D) | 26,453 |
| Open | 1.57 |
| Previous Close | 1.56 |
| Day's Range | 1.57 - 1.67 |
| 52-Week Range | 1.45 - 5.30 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PLUR
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. Its product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal ce...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 30, 2003
Employees 127
Stock Exchange NasdaqCM
Ticker Symbol PLUR
Website https://www.pluri-biotech.com
Financial Performance
In 2025, Pluri's revenue was 1.34M, an increase of 309.82% compared to the previous year's 326K. Earnings were -22.58M, an increase of 8.11%.
Financial StatementsEarnings Surprise
Pluri has released their quarterly earnings on Nov 12, 2025:
- Revenue of $167K misses estimates by $0, with -60.89% YoY decline.
- EPS of -0.65 exceeds estimates by 0.09, with 70.98% YoY growth.
Page 1 of 2